- Case report
- Open Access
Cyclosporine-A therapy-induced multiple bilateral breast and accessory axillary breast fibroadenomas: a case report
© Darwish et al; licensee BioMed Central Ltd. 2010
- Received: 21 October 2009
- Accepted: 11 August 2010
- Published: 11 August 2010
Breast adenoma is common. However, in the setting of post-transplantation immune suppression it may be expressed differently.
A 35-year-old Sudanese woman, with a history of renal transplantation two and half years prior to presentation, was on a single immune suppression therapy in the form of cyclosporine-A since the transplantation. During a regular follow-up visit, she was noticed to have gingival hypertrophy and bilateral breast and axillary swellings. She underwent successful surgical resection of the bilateral fibroadenomas.
Cyclosporine-A therapy post renal transplantation is associated with an increased incidence of benign breast changes as fibroadenoma. Regular follow-up and appropriate selection of immunosuppressant therapy are essential in the post transplantation management of these patients.
- Inflammatory Breast Cancer
- Serum Prolactin Level
- Breast Change
- Accessory Breast
The presence of bilateral breast fibroadenoma is rare. To the best of our knowledge, there are no previous reports of bilateral breast fibroadenoma associated with accessory axillary breast fibroadenoma in the English medical literature. We present the case of a woman with bilateral breast fibroadenoma secondary to cyclosporine-A therapy post renal transplantation.
A 35-year-old Sudanese woman presented to the Surgical Out-patient Department at Soba University Hospital, Khartoum, Sudan with bilateral breast and axillary swellings. Her condition started one year prior to presentation with a small painless right breast lump slowly increasing in size. It was not considered necessary by our patient to report it during her regular follow-up until seven months later when she noticed multiple small painless nodules on the left breast. She mentioned these lumps to the nephrologist in the following visit. There was no nipple discharge, local skin changes or variation in size with menstruation. One month later she noted bilateral painless axillary swellings that started to increase in size.
Our patient was diagnosed with end-stage renal failure of unidentified etiology three years prior to presentation. She underwent regular hemodialysis sessions before kidney transplantation two years prior to presentation. Her post-operative recovery was uneventful and she was commenced on cyclosporine-A (175 mg/day). She continued to attend regular follow-ups post transplantation. After two years of follow-up, she was found to have gum hypertrophy with no associated pain, bleeding or oral complains.
Her menarche was at the age of 16. She had a regular menstrual cycle and unremarkable adolescence. She had normal breast development, with no past or family history of breast disorders. She never used contraceptive pills.
Full blood count, liver function test, kidney function test, chest X-ray and echocardiogram showed no abnormalities. Serum prolactin level was also within normal range. Bilateral breast and axillary ultrasound examination supported the clinical findings suggestive of multiple fibroadenomas.
She underwent excision of multiple bilateral breast and axillary fibroadenomas through multiple skin incisions. She had a good post-operative recovery and wound healing. Histopathological examination of all excised masses confirmed the diagnosis of fibroadenomas.
The association between post-renal transplant cyclosporine-A therapy and breast changes is described in the medical literature [1, 2]. These changes can be focal or generalized depending on the pathology. Focal changes commonly occur in the form of fibroadenoma, which may be single, multiple, unilateral or bilateral. Low-grade phylloides tumor is another, less common, focal breast change that is associated with cyclosporine-A therapy. A diffuse pattern usually occurs in the form of multiple nodularity, fibrocystic disease or a more uniform generalized pattern with histological features similar to those found in men with gynecomastia [3, 4]. Another form of diffuse breast changes is generalized painful breast hypertrophy. This has to be differentiated from inflammatory breast cancer, infiltrative lymphoma and leukemic breast disease by performing a meticulous triple assessment to excluded malignancy in these patients[3, 5].
Cyclosporine is also well known to cause gingival hypertrophy as a direct action of the drug or its metabolites on the gingival fibroblasts. A similar mechanism of action may take place in the breast causing breast hypertrophy and fibroadenomata, which could explain the breast changes in our patient. Both cyclosporine-A and feldipine (a calcium antagonist) are reported to induce hypertrophy by causing hyperprolactinemia supported by a raised serum prolactin level post mammoplasty. The fact that this woman had a normal serum prolactin level makes this explanation less likely. Several cyclosporine-A binding proteins are identified in lymphoid and non-lymphoid cells [3, 6]. These proteins are claimed to be related to the development of T-cell lymphoma in some patients post renal transplant on cyclosporine-A therapy .
Discontinuing the cyclosporine may induce some improvement in early cases, but the breast may not return to pre-transplantation size due to the established breast fibrosis. In some patients where the degree of gynecomastia is small and/or the abnormalities are focal as fibroadenomas, which can be removed surgically, modification of immunosuppressive regimen is usually not necessary. However, in our patient with the presence of multiple fibroadenomas in every breast tissue including the accessory breasts in addition to the gingival hypertrophy, a shift to another immunosuppressive agent (tacrolimus) was found to be a reasonable decision.
Cyclosporine-A therapy is associated with breast fibroblast proliferation and breast fibroadenoma. Awareness of the association between cyclosporine-A and fibroadenomas should help to achieve the correct diagnosis in patients post transplantation without subjecting them to unnecessary procedures. Early conversion to tacrolimus should be considered in patients who appear to be developing cyclosporine-A induced breast disease and gingival hypertrophy.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Muttarak M, Peh WC, Chaiwun B, Lumlertgul D: Multiple bilateral giant fibroadenomas associated with cyclosporine A therapy in a renal transplant recipient. Australas Radiol. 2001, 45 (4): 517-519. 10.1046/j.1440-1673.2001.00970.x.View ArticlePubMedGoogle Scholar
- Weinstein SP, Orel SG, Collazzo L, Conant EF, Lawton TJ, Czerniecki B: Cyclosporin A-induced fibroadenomas of the breast: report of five cases. Radiology. 2001, 220 (2): 465-468.View ArticlePubMedGoogle Scholar
- Cyrlak D, Pahl M, Carpenter SE: Breast imaging case of the day. Multiple giant fibroadenomas associated with cyclosporin A therapy. Radiographics. 1999, 19 (2): 549-551.View ArticlePubMedGoogle Scholar
- Campbell A, Moazami N, Ditkoff BA, Kurtz E, Estabrook A, Schnabel F: Short-term outcome of chronic immunosuppression on the development of breast lesions in premenopausal heart and lung transplant patients. J Surg Res. 1998, 78 (1): 27-30. 10.1006/jsre.1998.5414.View ArticlePubMedGoogle Scholar
- Son EJ, Oh KK, Kim EK, Cho N, Lee JD, Kim SH: Characteristic imaging features of breast fibroadenomas in women given cyclosporin A after renal transplantation. J Clin Ultrasound. 2004, 32 (2): 69-77. 10.1002/jcu.10233.View ArticlePubMedGoogle Scholar
- Kanaan N, Goffin E: Multiple bilateral fibroadenomas of the breasts requiring mastectomy in a renal transplant patient. Clin Nephrol. 2004, 61 (2): 151-154.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.